Salim, MD

Schedule Online
Lipid Management Calculator — ACC/AHA 2019 · AACE 2025
Hyperlipidemia Management Decision Support
ACC/AHA 2019 AACE 2025

Lipid Management Decision Support Calculator

Enter your patient's ASCVD risk score and lipid values to generate evidence-based statin recommendations, LDL-C goals, and a printable clinical note. Integrates risk-enhancing factors and CAC scoring per current guidelines.

ACC/AHA 2019 Primary Prevention AACE 2025 Dyslipidemia CPG AHA/ACC 2018 Cholesterol CAC Score Integration
1
ASCVD Risk & Lipid Values
Core inputs — drives all downstream recommendations
▼
ℹ️ How to find these values
ASCVD Risk: Use your institution's Pooled Cohort Equations calculator or ACC ASCVD Risk Estimator Plus (tools.acc.org) and enter the 10-year % below.  Lipids: From the most recent fasting lipid panel.  Established ASCVD: Prior MI, ACS, stable angina, coronary revascularization, stroke, PAD.
A10-Year ASCVD Risk (Pooled Cohort Equations)
%
No — Primary Prevention
Yes — Secondary Prevention
Yes — Very High-Risk ★
★ Very High-Risk ASCVD (AACE 2025): Prior ACS/MI within 2 yrs PLUS any of: polyvascular disease, recurrent major ASCVD events (≥2), diabetes, CKD (eGFR <60), or LDL-C ≥70 mg/dL on maximally tolerated statin.
BLipid Panel
CAdditional Clinical Context
DConfirm Risk Tier  Auto-selected from PCE — override if needed
🟢
Low Risk
PCE <5%
🟡
Borderline
PCE 5–7.5%
🟠
Intermediate
PCE 7.5–20%
🔴
High Risk
PCE ≥20%
🔴
Secondary Prev.
Est. ASCVD
🟣
Very High-Risk
Multi-event / AACE
2
Risk-Enhancing Factors
Key for borderline & intermediate risk decisions — not in standard PCE
▼
💡 Why this section matters
Per ACC/AHA 2019: In borderline (5–7.5%) or intermediate (7.5–20%) risk patients, the presence of risk-enhancing factors should tip the decision toward statin therapy. The Pooled Cohort Equations do not incorporate these — this is where clinical judgment is applied.
3
Coronary Artery Calcium (CAC) Score
The key reclassifier — can tip statin decisions in either direction
▼
🔬 Clinical Role of CAC
ACC/AHA 2019: CAC = 0 supports withholding statins (unless DM, active smoking, or strong family history). CAC ≥100 or ≥75th percentile strongly supports statin initiation or intensification.

AACE 2025: CAC ≥300 or ≥75th MESA percentile for age/sex/race is a major risk-enhancing factor warranting high-intensity statin regardless of PCE tier.
Not obtained
Yes — enter score
Ordered / Pending
4
Current Lipid-Lowering Therapy
Determines next-step recommendations
▼
None
Low-intensity
Moderate-intensity
High-intensity
Statin Intensity Reference
IntensityLDL-C ReductionAgents & Doses
HIGH≥50%Atorvastatin 40–80 mg • Rosuvastatin 20–40 mg
MODERATE30–49%Atorvastatin 10–20 mg • Rosuvastatin 5–10 mg • Pravastatin 40–80 mg • Simvastatin 20–40 mg
LOW<30%Simvastatin 10 mg • Pravastatin 10–20 mg • Fluvastatin 20–40 mg
5
Shared Decision-Making & Lifestyle
Documents the clinical discussion for your note
▼
Counseling Provided Today
DECISION SUPPORT — LIVE
⚕️

Enter the 10-year ASCVD risk score and lipid values above to generate evidence-based recommendations.

Risk-enhancing factors and CAC score update results automatically.

⚠️ Clinical Decision Support Tool — Not a substitute for clinical judgment. This calculator is intended to assist clinicians in applying ACC/AHA 2019, AACE 2025, and AHA/ACC 2018 cholesterol guidelines. Recommendations must be interpreted in the context of the individual patient. Always verify drug dosing, interactions, and contraindications. LipidCalc does not collect or transmit patient data.

Disclaimer: The information provided on this website is for general educational and informational purposes only and is not intended to be a substitute for professional medical advice. 

©Copyright 2025 All Rights Reserved I Salim,MD®